These results were consistent with pre-clinical data showing that intermittent treatment with ceralasertib induced a decrease of intra-tumoural CD8 + and CD4 + T-cells, and the activation of a type I interferon response causing PD-L1 upregulation and tumour sensitization to the combination therapy [54]. The gene discussed is CD8A; the disease is neoplasm.